Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Japan to Push 2024 Reform Debate by Using Price “Maintenance” and “Raise” Rules: PM
October 26, 2023
- Japan to Deliberate Pricing Measures for Stable Drug Supplies: Draft Economic Package
October 25, 2023
- Sawai’s Misconduct Severely Undermines Credibility of Generics: Health Minister
October 25, 2023
- Panel Approves Revision to Basic Blood Product Policy; Change to Take Effect Next April
October 24, 2023
- Japan PM Vows to Review Official Prices, Eyeing Wage Hikes
October 24, 2023
- Japan Panel Clears Additional Usages for Adcetris, Opdivo, and More
October 24, 2023
- PMDA’s New Mid-Term Plan to Push Pediatric, Orphan Drug Development to Counter Losses
October 23, 2023
- Japan to Continue Accepting GLP Data from UK under New Bilateral Deal: MHLW
October 23, 2023
- Chuikyo Wants Sakigake Premium Review as a Package with Regulatory Reform
October 23, 2023
- China Formally Arrests Astellas Employee, Japan Urges Immediate Release
October 20, 2023
- Japan to Buy 10 Million More Doses of Pfizer/Moderna COVID Jabs
October 19, 2023
- Health Minister Requests 8 Makers to Bolster Supplies of Antitussive, Expectorant Agents
October 19, 2023
- Leqembi’s Initial Pricing Won’t Factor in Benefits in Long-Term Care
October 19, 2023
- Chuikyo at Odds over Handling of Startups in PMP, Timing of Deferred Price Cuts
October 19, 2023
- Medipharma Might Face Administrative Penalty over Trial Data Tampering
October 18, 2023
- Average Price Gap for 2024 Revision Looks to Be Lower than 7.0%: Wholesalers
October 18, 2023
- AMED Group to Draft Master Protocols Guidelines by March-End, Frets Further Drug Lag/Loss
October 17, 2023
- MHLW Sets Up Hotline for Production Site Change for Supply-Crippled Drugs
October 17, 2023
- Health Minister Laments Drug Lag/Loss, Stresses Need for Govt-Driven Innovation Ecosystem
October 16, 2023
- MHLW Regulatory Panel OKs New Procedures for Post-Approval Manufacturing Changes
October 16, 2023
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…